Advertisement
ORMP vs SDEV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ORMP is a Buy and SDEV is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ORMP’s FA Score shows that 1 FA rating(s) are green whileSDEV’s FA Score has 2 green FA rating(s).
- ORMP’s FA Score: 1 green, 4 red.
- SDEV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ORMP’s TA Score shows that 3 TA indicator(s) are bullish while SDEV’s TA Score has 4 bullish TA indicator(s).
- ORMP’s TA Score: 3 bullish, 6 bearish.
- SDEV’s TA Score: 4 bullish, 6 bearish.
Price Growth
ORMP (@Biotechnology) experienced а -10.77% price change this week, while SDEV (@Investment Managers) price change was -12.21% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.54%. For the same industry, the average monthly price growth was -1.96%, and the average quarterly price growth was +3.26%.
The average weekly price growth across all stocks in the @Investment Managers industry was -2.33%. For the same industry, the average monthly price growth was -3.81%, and the average quarterly price growth was -8.17%.
Reported Earning Dates
ORMP is expected to report earnings on Aug 12, 2026.
Industries' Descriptions
@Biotechnology (-1.54% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Investment Managers (-2.33% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
| ORMP | SDEV | ORMP / SDEV | |
| Capitalization | 147M | 32.8M | 448% |
| EBITDA | 55.9M | -32.81M | -170% |
| Gain YTD | 35.684 | -79.610 | -45% |
| P/E Ratio | 1.41 | N/A | - |
| Revenue | 2M | 0 | - |
| Total Cash | 15.8M | N/A | - |
| Total Debt | 860K | N/A | - |
ORMP | SDEV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 1 Undervalued | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 97 | |
SMR RATING 1..100 | 36 | 11 | |
PRICE GROWTH RATING 1..100 | 41 | 46 | |
P/E GROWTH RATING 1..100 | 88 | 13 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ORMP's Valuation (1) in the Pharmaceuticals Other industry is significantly better than the same rating for SDEV (82) in the Biotechnology industry. This means that ORMP’s stock grew significantly faster than SDEV’s over the last 12 months.
SDEV's Profit vs Risk Rating (97) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that SDEV’s stock grew similarly to ORMP’s over the last 12 months.
SDEV's SMR Rating (11) in the Biotechnology industry is in the same range as ORMP (36) in the Pharmaceuticals Other industry. This means that SDEV’s stock grew similarly to ORMP’s over the last 12 months.
ORMP's Price Growth Rating (41) in the Pharmaceuticals Other industry is in the same range as SDEV (46) in the Biotechnology industry. This means that ORMP’s stock grew similarly to SDEV’s over the last 12 months.
SDEV's P/E Growth Rating (13) in the Biotechnology industry is significantly better than the same rating for ORMP (88) in the Pharmaceuticals Other industry. This means that SDEV’s stock grew significantly faster than ORMP’s over the last 12 months.
| ORMP | SDEV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| Advances ODDS (%) | 21 days ago 82% | 22 days ago 84% |
| Declines ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 90% |
Advertisement
SDEV and
Correlation & Price change
A.I.dvisor indicates that over the last year, SDEV has been loosely correlated with ALP. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if SDEV jumps, then ALP could also see price increases.
| Ticker / NAME | Correlation To SDEV | 1D Price Change % | ||
|---|---|---|---|---|
| SDEV | 100% | -4.96% | ||
| ALP - SDEV | 38% Loosely correlated | -15.62% | ||
| ALT - SDEV | 30% Poorly correlated | -3.65% | ||
| ORMP - SDEV | 29% Poorly correlated | -7.33% | ||
| RPC - SDEV | 28% Poorly correlated | -2.03% | ||
| RVMD - SDEV | 28% Poorly correlated | -7.56% | ||
More | ||||